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12 The Journal of Thoracic and Cardioackground: Most patients with pathologic stage Ia non–small cell lung carcinoma
ave a good prognosis, and adjuvant chemotherapy is currently not being used in the
anagement of this stage of the disease. However, if significant negative prognostic
actors become evident in patients with pathologic stage Ia non–small cell lung
arcinoma, patients with negative prognostic factors should have adjuvant treatment
fter surgery.
ethods: We analyzed 335 cases of pathologic stage Ia non–small cell lung
arcinoma treated between 1988 and 2003 by complete resection. The pathologic
tage Ia non–small cell lung carcinomas comprised 259 adenocarcinomas, 65
quamous cell carcinomas, and 11 large cell neuroendocrine carcinomas. The
rognostic impact of various clinical variables was investigated by the Cox propor-
ional hazards multivariable regression model.
esults: Univariate analysis showed that large cell neuroendocrine carcinoma his-
ology, old age, large tumor size, male gender, and smoking predicted poorer overall
urvival. Large cell neuroendocrine carcinoma had a significantly poorer prognosis
han other non–small cell carcinomas. Multivariate analysis revealed that large cell
euroendocrine carcinoma was predictive of poorer overall survival (P  .0200,
azard ratio 2.787).
onclusions: Large cell neuroendocrine histology has a significant adverse prog-
ostic impact on pathologic stage Ia non–small cell carcinoma. Therefore, surgical
esection alone represents insufficient treatment for large cell neuroendocrine car-
inoma, even for pathologic stage Ia disease.
on–small cell lung carcinoma (NSCLC) includes a wide variety of histo-
logic types. Complete surgical resection is recognized as the most effective
treatment for NSCLC. Although early clinical trials did not identify a
enefit from adjuvant chemotherapy,1-3 more recent clinical trials have demon-
trated a survival advantage for patients receiving adjuvant chemotherapy.4,5 Most
atients with pathologic stage Ia NSCLC have a better prognosis than patients with
dvanced stages, and usually they do not require adjuvant chemotherapy. However,
f there are categories of NSCLC with a poor prognosis even in pathologic stage Ia,
atients with this class of disease should receive adjuvant therapy after complete
urgical resection. In 1999 the World Health Organization6 classified large cell
euroendocrine carcinoma (LCNEC) as a variant of large cell carcinomas. Although
CNEC falls between atypical carcinoid and small cell lung carcinoma on the
pectrum of clinical aggressiveness in pulmonary neuroendocrine tumors.7,8 it is not
lucidated whether LCNEC is a poor prognostic factor in stage Ia NSCLC or not.
n the present study, we analyzed prognostic factors including LCNEC, the new
vascular Surgery ● August 2006
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TSistologic type, in addition to several clinical variables in
athologic stage Ia NSCLC.
atients and Methods
e retrospectively analyzed clinical data from 335 patients with
rimary lung carcinoma diagnosed as pathologic stage Ia NSCLC
ho underwent complete surgical resection with systematic lymph
ode dissection without adjuvant chemotherapy at Chiba Univer-
ity Hospital between 1988 and 2003. We excluded patients with
imited surgical resection or incomplete resection. The pathologic
tage Ia NSCLC consisted of 259 adenocarcinomas, 65 squamous
ell carcinomas, and 11 LCNECs. Patient gender, age, smoking
ndex, tumor size, tumor location, surgical procedure, pathologic
NM stage, and patient outcome were determined from the med-
cal records.
tatistical Analysis
he Fisher exact test was used to compare binomial proportions.
he 2 test was used to assess differences in gender, tumor site,
nd surgical methods. The unpaired t test was used to detect
ignificant differences between patients with LCNEC and patients
ith other NSCLCs with respect to patient age, smoking index,
ABLE 1. Patient characteristics of pathologic stage Ia
SCLCs
No. of cases (%)
Age (y), mean (range) 63 (36-83)
75 301 (89.9%)
75 34 (10.1%)
Gender
Male (%) 186 (55.5%)
Female (%) 149 (44.5%)
Smoking index, mean (range) 490 (0-3600)
0 151 (45.1%)
1 184 (54.9%)
Tumor size (cm) mean (range) 2.0 (0.1-3.0)
2 cm 185 (55.2%)
2 cm 150 (44.8%)
Tumor site
Right 191 (57.0%)
Left 144 (43.0%)
Histology
LCNEC 11 (3.3%)
Other NSCLC 324 (96.7%)
Operation
Lobectomy 330 (98.5%)
Bilobectomy 5 (1.5%)
CNEC, Large cell neuroendocrine carcinoma; NSCLC, non–small cell lung
Abbreviations and Acronyms
LCNEC large cell neuroendocrine carcinoma
NSCLC non–small cell lung carcinomaarcinoma. 
The Journal of Thoracicnd tumor size. Survival time, calculated from the date of surgery
ntil the time of death, was evaluated by the Kaplan-Meier
ethod. The curves obtained were compared with the log-rank
est. The prognostic impact of the following clinical variables was
nvestigated by the Cox proportional hazards multivariable regres-
ion model: gender (male vs female), age (75 years old versus
75 years old), smoking index (0 versus 1), histologic type
LCNEC vs other NSCLC), tumor size (2 cm vs 2 cm), and
umor site (right vs left).
esults
n this study, patients’ characteristics are shown (Table 1).
The 5-year overall survival was 54.5% for patients with
CNEC and 89.3% for patients with other NSCLCs (Figure
). Patients with LCNEC had a significantly lower overall
urvival than did patients with other types of NSCLC (P 
0012).
Univariate analyses of survival were performed to deter-
ine predictors of overall survival in patients with patho-
ABLE 2. Univariate analyses of survival
Overall survival
P value Hazard ratio 95% CI
istology*
LCNEC .0026 3.650 1.570-8.485
ge† 75 years old .0005 2.992 1.616-5.537
umor size‡ 2 cm .0011 2.309 1.395-3.831
ender§ male .0028 2.369 1.347-4.167
moking index 1 .0037 2.237 1.299-3.846
ite¶ right .0671 1.618 0.967-2.708
I, Confidence interval; LCNEC, large cell neuroendocrine carcinoma.
Histologic type (LCNEC vs other NSCLC); †Age (75 years old vs 75
ears old); ‡Tumor size (2 cm vs 2 cm); §Gender (male vs female);
igure 1. Analysis of overall survival indicates that patients with
athologic stage Ia LCNEC had a significantly poorer prognosis
han patients with other types of pathologic stage Ia NSCLC.
CNEC, Large cell neuroendocrine carcinoma; NSCLC, non–small
ell lung carcinoma.Smoking index (0 vs 1); ¶Site (right vs left).
and Cardiovascular Surgery ● Volume 132, Number 2 313
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TSogic stage Ia NSCLC (Table 2). The following factors
ignificantly decreased overall survival: LCNEC histologic
ype, age 75 years or older, tumor size greater than 2 cm,
ale gender, and smoking index of 1 or more.
Multivariate analyses of survival revealed that LCNEC
istologic type, tumor size greater than 2 cm, and age 75
ears or older markedly decreased overall survival (Table 3).
iscussion
he present study revealed that patients with stage Ia LCNEC
ad a significantly poorer prognosis than patients with other
SCLCs and that large cell neuroendocrine histology has a
ignificant adverse prognostic impact on stage Ia NSCLC.
hese results suggest that surgical resection alone repre-
ents inadequate treatment for patients with LCNEC, even if
t is stage Ia disease, and that patients with stage Ia LCNEC
ay require adjuvant treatment.
Initial studies of patients with NSCLC failed to demon-
trate any survival benefit associated with adjuvant chemo-
herapy.1-3 However, two recent prospective randomized
linical trials have reported improved survival in patients
ith NSCLC receiving adjuvant chemotherapy.
In a study of oral uracil-tegafur for 2 years versus no
reatment in patients with completely resected pathologic
tage Ia pulmonary adenocarcinoma, Kato and associates4
eported that adjuvant chemotherapy with uracil-tegafur im-
roved survival, especially in stage T2 disease. In a study of
or 4 cycles of cisplatin-based chemotherapy versus obser-
ation, Arriagada and associates5 reported that cisplatin-
ased adjuvant chemotherapy improved survival among pa-
ients with resected stage Ia, 2 and 3 NSCLC.
These studies thus demonstrate that patients with NSCLCs,
s well as patients with small cell lung carcinomas, require
djuvant chemotherapy. Although these studies supported
he routine use of adjuvant chemotherapy in patients with
dvanced NSCLC, the studies did not completely elucidate
hether adjuvant chemotherapy would also be efficacious
ABLE 3. Multivariate analyses for survivals
Overall survival
P value Hazard ratio 95% CI
istology*
LCNEC .0200 2.787 1.175-6.609
ge† 75 years old .0008 2.926 1.565-5.469
umor size‡ 2 cm .0080 1.988 1.196-3.311
ender§ male .2246 1.736 0.713-4.231
moking index 1 .6191 1.242 0.529-2.915
ite¶ right
I, Confidence interval; CNEC, large cell neuroendocrine carcinoma. *His-
ologic type (LCNEC vs other NSCLC); †Age (75 years old vs 75 years
ld); ‡Tumor size (2 cm vs 2 cm); §Gender (male vs female); Smoking
ndex (0 vs 1); ¶Site (right vs left).or patients with stage Ia NSCLC. The study by Kato and t
14 The Journal of Thoracic and Cardiovascular Surgery ● Augussociates4 failed to identify a significant difference in sur-
ival between patients receiving adjuvant chemotherapy
nd control patients with stage Ia disease, although the study
id find a survival benefit from adjuvant chemotherapy for
atients with stage 1b disease. Currently, patients with stage
a NSCLC do not receive adjuvant chemotherapy because
tage Ia disease in general has a comparatively good prog-
osis. However, adjuvant chemotherapy might be appropri-
te for a subset of patients with stage Ia NSCLC, whose
umors have a very poor prognosis.
We9 have previously reported that LCNEC appears to be
more clinically aggressive tumor than classic large cell
arcinoma, LCNEC has a poorer prognosis than classic
arge cell carcinoma, and the identification of neuroendo-
rine histologic features in tumor tissue from patients diag-
osed with large cell carcinoma of the lung have clinical
elevance. In a second study, we10 found that adjuvant
hemotherapy is effective for patients with LCNEC. On this
asis, we plan in the future to routinely administer adjuvant
hemotherapy to patients with LCNEC. However, this sec-
nd study did not elucidate whether patients with pathologic
tage Ia LCNEC require adjuvant chemotherapy.
In 1991, Travis and associates11 published the first study
dentifying LCNEC as a distinct type of pulmonary neu-
oendocrine tumor; they reported that patients with LCNEC
ad a survival worse than that of patients with atypical
arcinoid and comparable with that of patients with small
ell lung carcinoma. Since then, although some studies have
eported no difference in prognosis between LCNEC and
ther NSCLCs,12 most reports have confirmed that LCNEC
s an aggressive tumor associated with a very poor progno-
is.9,13-18 Although it was not elucidated why patients with
CNEC had a very poor prognosis, we19 have previously
eported that LCNEC cases exhibited an increased Ki-67
abeling index and an increased mitotic rate. The Ki-67
uclear antigen, which is associated with cell proliferation,
s detectable in the nucleus of cycling (G1, S, G2 and
-phase) cells but absent in resting (G0 phase) cells. Ex-
erimental evidence indicates that biologically active tu-
ors express high levels of Ki-67 nuclear antigen.20,21
hese findings together suggest that LCNEC has a higher
evel of proliferative activity than other NSCLCs, and it is
ssociated with poor prognoses of patients with LCNEC.
Few studies have evaluated adjuvant chemotherapy for
CNEC. In 2001, we10 reported that adjuvant chemother-
py was effective for patients who had large cell carcinomas
ith neuroendocrine features, including LCNEC. Subse-
uently, other studies have concluded that adjuvant chemo-
herapy is necessary for patients with LCNEC.22,23 These
ndings provide confirmation of the results of the present
tudy.
In this study, we revealed that even with stage Ia disease,
he prognosis of patients with LCNEC was different from
st 2006
t
v
t
e
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
Iyoda et al General Thoracic Surgery
G
TShat of other NSCLC, although LCNEC is classified as a
ariant of NSCLC. Therefore, we should consider adjuvant
reatment after complete resection for patients with LCNEC,
ven if it is pathologic stage Ia disease.
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